Letter to the Editor

Fatal Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic, Androgen-independent Prostate Cancer

Authors: Cheng-Jui Lin, MD, Ruey-Kuen Hsieh, MD, Ken-Hong Lim, MD, Han-Hsiang Chen, MD, Yi-Chou Cheng, MD, Chih-Jen Wu, MD

Abstract

To the Editor:


Acute tumor lysis syndrome (TLS) is a serious, potentially life-threatening complication of cancer therapy requiring prompt recognition and aggressive management. It occurs particularly in patients with lymphoproliferative diseases during potent myelosuppressive therapy.1 To our knowledge, acute spontaneous TLS in solid tumors is extremely rare and has not been reported in prostate carcinoma.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3–11.
 
2. Sorscher SM. Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer. Cancer Chemother Pharmacol 2004;54:191–192.
 
3. Wright JL, Lin DW, Dewan P, et al. Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int J Urol 2005;12:1012–1013.
 
4. Tanvetyanon T, Choudhury AM. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol 2004;171:1627.